Skip to main content

Table 1 Dose-effect relationships of drug combinations in human androgen-independent prostate cancer cell line LNCaP C4-2B: Gefitinib (Ge), Lapatinib (La) and Cyclopamine (Cy).

From: Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling

Treatment Parameters CI value at Range Significance
  Dm m r ED50 ED75 ED90   
Ge+Cy (12:1) 9.5 0.44 0.94 0.22 0.06 0.02 0.1–0.3 strong synergism
La+Cy (7:1) 5.8 0.44 0.94 0.14 0.06 0.03 0.1–0.3 strong synergism